EX-99.1 2 nxgn-ex991_6.htm EX-99.1 nxgn-ex991_6.htm

Exhibit 99.1

 

 

 

 

 

FOR IMMEDIATE RELEASE

October 30, 2018

 

NextGen Healthcare, Inc. Reports Fiscal 2019 Second Quarter Results

IRVINE, Calif. – (BUSINESS WIRE) – NextGen Healthcare, Inc. (NASDAQ: NXGN) announced today its fiscal 2019 second quarter ended September 30, 2018 operating results.

 

"We continued to execute on our strategic plan in the second quarter of fiscal 2019, delivering another strong quarter of bookings including signing larger, more complex, subscription oriented deals.  These larger deals take longer to implement, causing a delay in revenue recognition, which combined with an uptick in attrition have resulted in a temporal shortfall in revenue. While we remain committed to our multi-year growth targets due to the strength or our bookings and pipeline along with solution enhancements coming to market, we are slightly adjusting guidance for this year,” commented Rusty Frantz, president and chief executive officer of NextGen Healthcare.

 

Fiscal 2019 Second Quarter Highlights

As a result of the adoption of Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers: Topic 606 (“ASC 606”), the GAAP comparisons below compare fiscal 2019 second quarter results under ASC 606 to the fiscal 2018 second quarter results under the legacy revenue guidance (“ASC 605”). A reconciliation of fiscal 2019 second quarter results from ASC 606 to ASC 605 can be found in the tables at the end of the press release.

 

On a GAAP basis, revenue for the fiscal 2019 second quarter of $130.3 million compared to $132.6 million a year-ago. On a pro forma basis under ASC 605, revenue for the fiscal 2019 second quarter was $129.4 million. 

 

On a GAAP basis, net income for the fiscal 2019 second quarter was $13.1 million, compared with net income of $8.0 million in the fiscal 2018 second quarter. On a pro forma basis under ASC 605, net income for the fiscal 2019 second quarter was $10.9 million.

 

On a GAAP basis, fully diluted net income per share was $0.20 in the fiscal 2019 second quarter compared with earnings per share of $0.13 for the same period a year ago.  On a non-GAAP basis, fully diluted earnings per share for the fiscal 2019 second quarter was $0.24 versus $0.22 reported in the second quarter a year ago. On a pro forma non-GAAP basis, under ASC 605, fully diluted earnings per share for the fiscal 2019 second quarter was $0.21.

 

Fiscal 2019 Financial Outlook

The company’s updated outlook for fiscal 2019 is now as follows:

 

Revenue of between $525 million and $535 million, from the previous range of $532 million to $548 million.

 

Non-GAAP EPS of between $0.70 and $0.74, from the previous range of $0.70 to $0.78.

 


 

Conference Call Information

NextGen Healthcare will host a conference call to discuss its fiscal 2019 second quarter results on Tuesday, October 30, 2018 at 5:00 PM ET (2:00 PM PT). Shareholders and interested participants may listen to a live broadcast of the conference call by dialing 866-750-8947 or 720-405-1352 for international callers, and referencing participant code 5520719 approximately 15 minutes prior to the call. A live webcast of the conference call will be available on the investor relations section of the company’s web site and an audio file of the call will also be archived for 90 days at investor.qsii.com. After the conference call, a replay will be available until November 1, 2018 and can be accessed by dialing 800-585-8367 or 404-537-3406 for international callers, and referencing participant code 5520719.

 

About NextGen Healthcare, Inc

NextGen Healthcare, Inc. provides a range of software, services, and analytics solutions to medical and dental group practices. The company's portfolio delivers foundational capabilities to empower physician success, enrich the patient care experience, and enable the transition to value-based healthcare. Visit www.nextgen.com for additional information.

 

Media Contact:
Colleen Edwards, 949-255-2600x75618
coedwards@nextgen.com

or

Investor Contact:

Westwicke Partners

Bob East or Asher Dewhurst

Westwicke Partners

443-213-0500

 

 

SAFE HARBOR PROVISIONS FOR FORWARD-LOOKING STATEMENTS

This news release may contain forward-looking statements within the meaning of the federal securities laws, including but not limited to, statements regarding future events, developments in the healthcare sector and regulatory framework, the Company's future performance, as well as management's expectations, beliefs, intentions, plans, estimates or projections relating to the future (including, without limitation, statements concerning revenue, net income, and earnings per share). Risks and uncertainties exist that may cause the results to differ materially from those set forth in these forward-looking statements. Factors that could cause the anticipated results to differ from those described in the forward-looking statements and additional risks and uncertainties are set forth in Part I, Item A of our most recent Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q, including but not limited to: the volume and timing of systems sales and installations; length of sales cycles and the installation process; the possibility that products will not achieve or sustain market acceptance; seasonal patterns of sales and customer buying behavior; impact of incentive payments under The American Recovery and Reinvestment Act on sales and the ability of the Company to meet continued certification requirements; uncertainties related to the future impact of U.S. tax reform; the impact of governmental and regulatory agency investigations; the development by competitors of new or superior technologies; the timing, cost and success or failure of new product and service introductions, development and product upgrade releases; undetected errors or bugs in software; product liability; changing economic, political or regulatory influences in the health-care industry; changes in product-pricing policies; availability of third-party


products and components; competitive pressures including product offerings, pricing and promotional activities; the Company's ability or inability to attract and retain qualified personnel; possible regulation of the Company's software by the U.S. Food and Drug Administration; changes of accounting estimates and assumptions used to prepare the prior periods' financial statements; disruptions caused by acquisitions of companies, products, or technologies; and general economic conditions. A significant portion of the Company's quarterly sales of software product licenses and computer hardware is concluded in the last month of a fiscal quarter, generally with a concentration of such revenues earned in the final ten business days of that month. Due to these and other factors, the Company's revenues and operating results are very difficult to forecast. A major portion of the Company's costs and expenses, such as personnel and facilities, are of a fixed nature and, accordingly, a shortfall or decline in quarterly and/or annual revenues typically results in lower profitability or losses. As a result, comparison of the Company's period-to-period financial performance is not necessarily meaningful and should not be relied upon as an indicator of future performance. These forward-looking statements speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

 

USE OF NON-GAAP FINANCIAL MEASURES

This news release contains certain non-GAAP (Generally Accepted Accounting Principles) financial measures, which are provided only as supplemental information. Investors should consider these non-GAAP financial measures only in conjunction with the comparable GAAP financial measures. These non-GAAP measures are not in accordance with or a substitute for U.S. GAAP. Pursuant to the requirements of Regulation G, the Company has provided a reconciliation of non-GAAP financial measures to the most directly comparable financial measure in the accompanying financial tables. Other companies may calculate non-GAAP measures differently than NextGen Healthcare, Inc., which limits comparability between companies. The Company believes that its presentation of non-GAAP diluted earnings per share provides useful supplemental information to investors and management regarding the Company's financial condition and results. The presentation of non-GAAP financial information is not intended to be considered in isolation or as a substitute for, or superior to, financial information prepared and presented in accordance with GAAP. The Company calculates non-GAAP diluted earnings per share by excluding net acquisition costs, amortization of acquired intangible assets, amortization of deferred debt issuance costs, restructuring costs, net securities litigation defense costs and settlement, share-based compensation, and other non-run-rate expenses from GAAP income before provision for income taxes. The Company utilizes a normalized non-GAAP tax rate to provide better consistency across the interim reporting periods within a given fiscal year by eliminating the effects of non-recurring and period-specific items, which can vary in size and frequency, and which are not necessarily reflective of the Company’s longer-term operations.

 

The normalized non-GAAP tax rate applied to fiscal year 2019 was 22.0%, compared to 30.5% for fiscal year 2018, which was updated as a result of the enactment of the new tax reform legislation on December 22, 2017. The determination of this rate is based on the consideration of both historic and projected financial results. The Company may adjust its non-GAAP tax rate as additional information becomes available and in conjunction with any other significant events occur that may materially affect this rate, such as merger and acquisition activity, changes in business outlook, or other changes in expectations regarding tax regulations.

 

The Company’s future period guidance in this release includes adjustments for items not indicative of the Company’s core operations. Such adjustments are generally expected to be of a nature similar to those adjustments applied to the Company’s historic GAAP financial results in the determination of the Company’s non-GAAP diluted earnings per share. Such adjustments, however, may be affected by changes in ongoing assumptions and judgments as to the items that are excluded in the calculation of non-GAAP adjusted net income and adjusted diluted earnings per share, as described in this release. The exact amount and probable significance of these adjustments, including net acquisition costs, net securities litigation defense costs, and other non-run-rate


expenses, are not currently determinable without unreasonable efforts, but may be significant. These items cannot be reliably quantified or forecasted due to the combination of their historic and expected variability. It is therefore not practicable to reconcile this non-GAAP guidance to the most comparable GAAP measures.

 

 

 

 


 

 

NEXTGEN HEALTHCARE, INC.

CONSOLIDATED STATEMENTS OF INCOME

(In thousands, except per share data)

(Unaudited)

 

 

Three Months Ended September 30,

 

 

Six Months Ended September 30,

 

 

2018

 

 

2017

 

 

2018

 

 

2017

 

Revenues:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Recurring

$

116,317

 

 

$

119,441

 

 

$

236,324

 

 

$

238,619

 

Software, hardware, and other non-recurring

 

14,004

 

 

 

13,166

 

 

 

27,197

 

 

 

24,910

 

Total revenues

 

130,321

 

 

 

132,607

 

 

 

263,521

 

 

 

263,529

 

Cost of revenue:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Recurring

 

47,172

 

 

 

47,699

 

 

 

95,325

 

 

 

96,157

 

Software, hardware, and other non-recurring

 

7,022

 

 

 

5,947

 

 

 

14,176

 

 

 

11,987

 

Amortization of capitalized software costs and acquired intangible assets

 

6,924

 

 

 

5,109

 

 

 

13,468

 

 

 

9,780

 

Total cost of revenue

 

61,118

 

 

 

58,755

 

 

 

122,969

 

 

 

117,924

 

Gross profit

 

69,203

 

 

 

73,852

 

 

 

140,552

 

 

 

145,605

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Selling, general and administrative

 

34,229

 

 

 

40,977

 

 

 

78,865

 

 

 

83,954

 

Research and development costs, net

 

18,371

 

 

 

19,527

 

 

 

40,499

 

 

 

39,516

 

Amortization of acquired intangible assets

 

1,121

 

 

 

2,012

 

 

 

2,289

 

 

 

4,059

 

Total operating expenses

 

53,721

 

 

 

62,516

 

 

 

121,653

 

 

 

127,529

 

Income from operations

 

15,482

 

 

 

11,336

 

 

 

18,899

 

 

 

18,076

 

Interest income

 

40

 

 

 

12

 

 

 

69

 

 

 

21

 

Interest expense

 

(769

)

 

 

(840

)

 

 

(1,499

)

 

 

(1,517

)

Other income (expense), net

 

237

 

 

 

15

 

 

 

611

 

 

 

(7

)

Income before provision for income taxes

 

14,990

 

 

 

10,523

 

 

 

18,080

 

 

 

16,573

 

Provision for income taxes

 

1,896

 

 

 

2,493

 

 

 

2,338

 

 

 

4,647

 

Net income

$

13,094

 

 

$

8,030

 

 

$

15,742

 

 

$

11,926

 

Net income per share:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

$

0.20

 

 

$

0.13

 

 

$

0.25

 

 

$

0.19

 

Diluted

$

0.20

 

 

$

0.13

 

 

$

0.24

 

 

$

0.19

 

Weighted-average shares outstanding:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

64,265

 

 

 

63,513

 

 

 

64,143

 

 

 

63,077

 

Diluted

 

64,857

 

 

 

63,530

 

 

 

64,362

 

 

 

63,089

 

 



NEXTGEN HEALTHCARE, INC.

CONSOLIDATED BALANCE SHEETS

(In thousands, except per share data)

(Unaudited)

 

 

 

September 30, 2018

 

 

March 31, 2018

 

ASSETS

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

32,387

 

 

$

28,845

 

Restricted cash and cash equivalents

 

 

7,331

 

 

 

2,373

 

Accounts receivable, net

 

 

85,548

 

 

 

84,962

 

Contract assets

 

 

10,253

 

 

 

 

Inventory

 

 

153

 

 

 

180

 

Income taxes receivable

 

 

5,976

 

 

 

8,122

 

Prepaid expenses and other current assets

 

 

16,987

 

 

 

17,180

 

Total current assets

 

 

158,635

 

 

 

141,662

 

Equipment and improvements, net

 

 

24,815

 

 

 

26,795

 

Capitalized software costs, net

 

 

31,805

 

 

 

26,318

 

Deferred income taxes, net

 

 

6,264

 

 

 

9,219

 

Contract assets, net of current

 

 

2,942

 

 

 

 

Intangibles, net

 

 

63,227

 

 

 

74,091

 

Goodwill

 

 

218,771

 

 

 

218,875

 

Other assets

 

 

29,226

 

 

 

18,795

 

Total assets

 

$

535,685

 

 

$

515,755

 

LIABILITIES AND SHAREHOLDERS' EQUITY

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

6,237

 

 

$

4,213

 

Contract liabilities

 

 

50,023

 

 

 

54,079

 

Accrued compensation and related benefits

 

 

18,885

 

 

 

27,910

 

Income taxes payable

 

 

18

 

 

 

73

 

Other current liabilities

 

 

43,883

 

 

 

48,317

 

Total current liabilities

 

 

119,046

 

 

 

134,592

 

Contract liabilities, net of current

 

 

 

 

 

1,173

 

Deferred compensation

 

 

5,951

 

 

 

6,086

 

Line of credit

 

 

42,000

 

 

 

37,000

 

Other noncurrent liabilities

 

 

13,254

 

 

 

13,494

 

Total liabilities

 

 

180,251

 

 

 

192,345

 

Commitments and contingencies

 

 

 

 

 

 

 

 

Shareholders' equity:

 

 

 

 

 

 

 

 

Common stock

 

 

 

 

 

 

 

 

$0.01 par value; authorized 100,000 shares; issued and outstanding 64,382 and 63,995 shares at September 30, 2018 and March 31, 2018, respectively

 

 

644

 

 

 

640

 

Additional paid-in capital

 

 

253,613

 

 

 

244,462

 

Accumulated other comprehensive loss

 

 

(1,692

)

 

 

(400

)

Retained earnings (1)

 

 

102,869

 

 

 

78,708

 

Total shareholders' equity

 

 

355,434

 

 

 

323,410

 

Total liabilities and shareholders' equity

 

$

535,685

 

 

$

515,755

 

 

 

(1)

Includes cumulative effect adjustment related to the adoption of ASC 606.

 



NEXTGEN HEALTHCARE, INC.

NON-GAAP FINANCIAL MEASURES

(In thousands, except per share data)

 

 

RECONCILIATION OF NON-GAAP DILUTED EARNINGS PER SHARE

 

 

Three Months Ended September 30,

 

 

Six Months Ended September 30,

 

 

2018

 

 

2017

 

 

2018

 

 

2017

 

Income before provision for income taxes - GAAP

$

14,990

 

 

$

10,523

 

 

$

18,080

 

 

$

16,573

 

Non-GAAP adjustments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Acquisition costs, net

 

315

 

 

 

633

 

 

 

1,949

 

 

 

1,182

 

Amortization of acquired intangible assets

 

5,409

 

 

 

5,820

 

 

 

10,865

 

 

 

11,268

 

Amortization of deferred debt issuance costs

 

178

 

 

 

269

 

 

 

355

 

 

 

538

 

Securities litigation defense costs and settlement, net of insurance

 

(5,715

)

 

 

118

 

 

 

(5,436

)

 

 

564

 

Share-based compensation

 

4,135

 

 

 

3,091

 

 

 

7,251

 

 

 

5,132

 

Other non-run-rate expenses*

 

691

 

 

 

 

 

 

2,639

 

 

 

263

 

Total adjustments to GAAP income before provision for income taxes:

 

5,013

 

 

 

9,931

 

 

 

17,623

 

 

 

18,947

 

Income before provision for income taxes - Non-GAAP

 

20,003

 

 

 

20,454

 

 

 

35,703

 

 

 

35,520

 

Provision for income taxes

 

4,401

 

 

 

6,239

 

 

 

7,855

 

 

 

10,834

 

Net income - Non-GAAP

$

15,602

 

 

$

14,215

 

 

$

27,848

 

 

$

24,686

 

Diluted net income per share - Non-GAAP

$

0.24

 

 

$

0.22

 

 

$

0.43

 

 

$

0.39

 

Weighted-average shares outstanding (diluted):

 

64,857

 

 

 

63,530

 

 

 

64,362

 

 

 

63,089

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

RECONCILIATION OF NON-GAAP DILUTED EARNINGS PER SHARE UNDER ASC 605

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income before provision for income taxes - Non-GAAP

 

20,003

 

 

 

 

 

 

 

35,703

 

 

 

 

 

Adjustments due to adoption of ASC 606

 

(2,898

)

 

 

 

 

 

 

(4,089

)

 

 

 

 

Income before provision for income taxes - Non-GAAP under ASC 605

 

17,105

 

 

 

 

 

 

 

31,614

 

 

 

 

 

Provision for income taxes

 

3,763

 

 

 

 

 

 

 

6,955

 

 

 

 

 

Net income - Non-GAAP under ASC 605

$

13,342

 

 

 

 

 

 

$

24,659

 

 

 

 

 

Diluted net income per share - Non-GAAP under ASC 605

$

0.21

 

 

 

 

 

 

$

0.38

 

 

 

 

 

Weighted-average shares outstanding (diluted):

 

64,857

 

 

 

 

 

 

 

64,362

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

* Other non-run-rate expenses for the three and six months ended September 30, 2018 consist primarily of severance and other employee-related costs not related to core operations. Other non-run-rate expenses for the six months ended September 30, 2017 consist primarily of professional services costs not related to core operations.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


We adopted Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers: Topic 606 (“ASC 606”) and all related amendments as of April 1, 2018 using the modified retrospective method for all contracts not completed as of the date of adoption. Results for reporting periods beginning after April 1, 2018 are presented under ASC 606, while prior period comparative information has not been adjusted and continue to be reported under the accounting standards in effect for those prior periods.

The impact of the adoption of ASC 606 on our consolidated statements of net income for the three and six months ended September 30, 2018, assuming that the previous revenue recognition guidance had been in effect, is summarized as follows:

 

 

 

 

Three Months Ended September 30, 2018

 

 

 

As reported under

 

 

Adjustments due to

 

 

As disclosed under

 

 

 

ASC 606

 

 

adoption of ASC 606

 

 

ASC 605

 

Revenues:

 

 

 

 

 

 

 

 

 

 

 

 

Subscription services

 

$

29,255

 

 

$

(2,377

)

 

$

26,878

 

Support and maintenance

 

 

39,594

 

 

 

(1,471

)

 

 

38,123

 

Managed services

 

 

23,527

 

 

 

3,067

 

 

 

26,594

 

Electronic data interchange and data services

 

 

23,941

 

 

 

(12

)

 

 

23,929

 

Total recurring revenues

 

 

116,317

 

 

 

(793

)

 

 

115,524

 

Software license and hardware

 

 

9,353

 

 

 

(276

)

 

 

9,077

 

Other non-recurring services

 

 

4,651

 

 

 

180

 

 

 

4,831

 

Total software, hardware, and other non-recurring revenues

 

 

14,004

 

 

 

(96

)

 

 

13,908

 

Total revenue

 

 

130,321

 

 

 

(889

)

 

 

129,432

 

Total cost of revenue

 

 

61,118

 

 

 

52

 

 

 

61,170

 

Gross profit

 

 

69,203

 

 

 

(941

)

 

 

68,262

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Selling, general and administrative

 

 

34,229

 

 

 

1,957

 

 

 

36,186

 

Research and development costs, net

 

 

18,371

 

 

 

 

 

 

18,371

 

Amortization of acquired intangibles

 

 

1,121

 

 

 

 

 

 

1,121

 

Total operating expenses

 

 

53,721

 

 

 

1,957

 

 

 

55,678

 

Income from operations

 

 

15,482

 

 

 

(2,898

)

 

 

12,584

 

Interest and other income, net

 

 

(492

)

 

 

 

 

 

(492

)

Income before provision for income taxes

 

 

14,990

 

 

 

(2,898

)

 

 

12,092

 

Provision for income taxes

 

 

1,896

 

 

 

(751

)

 

 

1,145

 

Net income

 

$

13,094

 

 

$

(2,147

)

 

$

10,947

 

 


 

 

Six Months Ended September 30, 2018

 

 

 

As reported under

 

 

Adjustments due to

 

 

As disclosed under

 

 

 

ASC 606

 

 

adoption of ASC 606

 

 

ASC 605

 

Revenues:

 

 

 

 

 

 

 

 

 

 

 

 

Subscription services

 

$

57,583

 

 

$

(3,952

)

 

$

53,631

 

Support and maintenance

 

 

80,842

 

 

 

(2,169

)

 

 

78,673

 

Managed services

 

 

49,797

 

 

 

6,100

 

 

 

55,897

 

Electronic data interchange and data services

 

 

48,102

 

 

 

(85

)

 

 

48,017

 

Total recurring revenues

 

 

236,324

 

 

 

(106

)

 

 

236,218

 

Software license and hardware

 

 

16,796

 

 

 

(843

)

 

 

15,953

 

Other non-recurring services

 

 

10,401

 

 

 

106

 

 

 

10,507

 

Total software, hardware, and other non-recurring revenues

 

 

27,197

 

 

 

(737

)

 

 

26,460

 

Total revenue

 

 

263,521

 

 

 

(843

)

 

 

262,678

 

Total cost of revenue

 

 

122,969

 

 

 

94

 

 

 

123,063

 

Gross profit

 

 

140,552

 

 

 

(937

)

 

 

139,615

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Selling, general and administrative

 

 

78,865

 

 

 

3,152

 

 

 

82,017

 

Research and development costs, net

 

 

40,499

 

 

 

 

 

 

40,499

 

Amortization of acquired intangibles

 

 

2,289

 

 

 

 

 

 

2,289

 

Total operating expenses

 

 

121,653

 

 

 

3,152

 

 

 

124,805

 

Income from operations

 

 

18,899

 

 

 

(4,089

)

 

 

14,810

 

Interest and other income, net

 

 

(819

)

 

 

 

 

 

(819

)

Income before provision for income taxes

 

 

18,080

 

 

 

(4,089

)

 

 

13,991

 

Provision for income taxes

 

 

2,338

 

 

 

(997

)

 

 

1,341

 

Net income

 

$

15,742

 

 

$

(3,092

)

 

$

12,650